Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cefiderocol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Shionogi | Biomedical Advanced Research and Development Authority
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Pharmacokinetics of IV Cefiderocol/Xeruborbactam In Renal Impairment
Details : Cefiderocol is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Bacterial Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 05, 2025
Lead Product(s) : Cefiderocol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Shionogi | Biomedical Advanced Research and Development Authority
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cefiderocol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cefiderocol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Gram-Negative Bacterial Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 17, 2023
Lead Product(s) : Cefiderocol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cefiderocol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Monaldi Hospital | Rutgers Robert Wood Johnson Medical School | Pisa University Hospital | Assaf-Harofeh Medical Center | Sheba Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cefiderocol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Carbapenem-resistant Bacterial Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 28, 2023
Lead Product(s) : Cefiderocol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Monaldi Hospital | Rutgers Robert Wood Johnson Medical School | Pisa University Hospital | Assaf-Harofeh Medical Center | Sheba Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cefiderocol
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Shionogi
Deal Size : Inapplicable
Deal Type : Inapplicable
Cefiderocol Plasma Concentrations in Patients Receiving Renal Replacement Therapy
Details : Cefiderocol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 13, 2022
Lead Product(s) : Cefiderocol
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Shionogi
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cefiderocol
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Shionogi | Keystone Bioanalytical | Indiana University Health Methodist Hospital | University of Pittsburgh Medical Center | University of Texas System
Deal Size : Inapplicable
Deal Type : Inapplicable
Cefiderocol Pharmacokinetics in Adult Patients With Cystic Fibrosis
Details : Cefiderocol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cystic Fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 06, 2022
Lead Product(s) : Cefiderocol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Shionogi | Keystone Bioanalytical | Indiana University Health Methodist Hospital | University of Pittsburgh Medical Center | University of Texas System
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cefiderocol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Shionogi
Deal Size : Inapplicable
Deal Type : Inapplicable
Cefiderocol PK in Patients on ECMO
Details : Cefiderocol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Sepsis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 09, 2021
Lead Product(s) : Cefiderocol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Shionogi
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cefiderocol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cefiderocol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Gram-Negative Bacterial Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 06, 2020
Lead Product(s) : Cefiderocol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cefiderocol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cefiderocol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Gram-Negative Bacterial Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 02, 2020
Lead Product(s) : Cefiderocol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cefiderocol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Shionogi
Deal Size : Inapplicable
Deal Type : Inapplicable
RCT Cefiderocol vs BAT for Treatment of Gram Negative BSI
Details : Cefiderocol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Sepsis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 11, 2019
Lead Product(s) : Cefiderocol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Shionogi
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cefiderocol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial Pneumonia
Details : Cefiderocol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pneumonia, Bacterial.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 05, 2019
Lead Product(s) : Cefiderocol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable